Posted by Michael Wonder on 27 Oct 2023
Health Canada authorises CSL's Hemgenix (etranacogene dezaparvovec) as first gene therapy for haemophilia B
26 October 2023 - CSL's Hemgenix is a one time, single dose treatment for adults with haemophilia B who require routine prophylaxis.
Global biotechnology leader CSL today announced that Health Canada has authorised Hemgenix (etranacogene dezaparvovec), the first and only gene therapy for the treatment of haemophilia B.
